Entera Bio Ltd(ENTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.35 | Insider Own | 20.2% | Shs Outstand | 173.9M | Perf Week | 9.59% |
| Market Cap | 0.56B | Forward P/E | - | EPS next Y | 8.38% | Insider Trans | - | Shs Float | 138.8M | Perf Month | 10.73% |
| Enterprise Value | 0.54B | PEG | - | EPS next Q | -0.07 | Inst Own | 18.1% | Short Float | 4% | Perf Quarter | 8.11% |
| Income | -0.02B | P/S | - | EPS this Y | -67% | Inst Trans | 8.61% | Short Ratio | 10.7 | Perf Half Y | 190.91% |
| Sales | 0.00B | P/B | 21.71 | EPS next 5Y | -17.2% | ROA | -87.02% | Short Interest | 5.55M | Perf YTD | 64.95% |
| Book/sh | 0.15 | P/C | 30.2 | EPS past 3/5Y | 18.28% 16.47% | ROE | -138.92% | 52W High | -23.81% ($4.20) | Perf Year | 13.48% |
| Cash/sh | 0.11 | P/FCF | - | Sales past 3/5Y | -32.07% -35.11% | ROIC | -227.35% | 52W Low | 251.64% ($0.91) | Perf 3Y | 384.85% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -36.92% | Gross Margin | - | Volatility(W/M) | 7.41% 7.51% | Perf 5Y | -24.88% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.22 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.98 | EPS Q/Q | -155.56% | Profit Margin | - | RSI (14) | 63.63 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.98 | Sales Q/Q | - | SMA20 | 13.88% ($2.81) | Beta | 1.51 | Target Price | $10 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/8/7 | SMA50 | 10.51% ($2.9) | Rel Volume | 0.56 | Prev Close | $3.12 |
| Employees | 22 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | -75% - | SMA200 | 67.82% ($1.91) | Avg Volume(3M) | 0.52M | Price | $3.2 |
| IPO | 2018/6/28 | Option/Short | Yes/Yes | Trades | 2242 | Volume | 292,685 | Change | 2.56% |
💊 This Israel-based biotech company focuses on oral delivery technology that transforms large-molecule drugs—previously available only as injections—into pill form. It is advancing its clinical pipeline around two lead candidates: EB613 for osteoporosis and EB612 for hypoparathyroidism. The company remains at the clinical stage with no product revenue yet.
Over the past 1 year, roughly in the middle
24% below its 1-year high.
Traded less than usual. That is 56% of its average volume.
ENTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -67.0% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -24.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 18.1%.
Tap to view numbers
It ranks #207 of 597 in the industry
Based on market cap of $557M.
MDXG#204 Mimedx Group Inc $566M PER - 
ANL#205 Adlai Nortye Group Ltd ADR $561M PER - 
STTK#206 Shattuck Labs Inc $558M PER - ENTX#207 Entera Bio Ltd $557M PER - 
NGNE#208 Neurogene Inc $551M PER - 
FAQ
What kind of company is ENTX?
ENTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ENTX?
The market cap of ENTX is approximately $557M, ranking 3,054 within its sector.
What is the 52-week high and low for ENTX?
ENTX has recorded a 52-week high of $4.20 and a low of $0.91.
